Day One Biopharmaceuticals Inc

NASDAQ DAWN

Download Data

Day One Biopharmaceuticals Inc Net Current Asset Value 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 1.57%

Day One Biopharmaceuticals Inc Net Current Asset Value 2 year CAGR is 1.57% for the Trailing 12 Months (TTM) ending March 31, 2024. Net current asset value is a financial metric that represents the excess of a company's current assets over its total liabilities. It is calculated by subtracting the total liabilities from the total current assets of a company. Net current asset value provides insights into the value that would be available to shareholders if the company were to liquidate its current assets and pay off its liabilities. This metric is used to assess the company's liquidity position and the potential value for shareholders in a liquidation scenario. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Day One Biopharmaceuticals Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2023 was 345,226,500.00, a 20.25% change year over year.
  • Day One Biopharmaceuticals Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2022 was 287,084,500.00, a 598.05% change year over year.
  • Day One Biopharmaceuticals Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2021 was -57,642,000.00.
NASDAQ: DAWN

Day One Biopharmaceuticals Inc

CEO Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date May 27, 2021
Location United States
Headquarters 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 174
Sector Healthcare
Industry Biotechnology
Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email